One notable study investigated the use of intrathecal idursulfase-IT, an enzyme replacement therapy ... for patients with neuronopathic MPS II (Hunter syndrome). Although the primary endpoint ...

The second asset they have is RGX-121 for the treatment of boys with MPS II (Hunter Syndrome ... the pivotal dose discontinued intravenous enzyme replacement therapy or remained treatment ...

Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.

Hunter syndrome results from the absence of an enzyme needed to break down cellular waste. Without it, waste builds up in the body, causing progressive damage to various systems. Get top local ...

RegenxBio said Tuesday that Kyoto, Japan’s Nippon Shinyaku Co. Ltd. will develop and commercialize its one-time gene therapies for Hunter syndrome ... nervous system. Enzyme replacement therapy ...

Aaron Taylor-Johnson in "Kraven the Hunter." Kraven the Hunter—the Marvel movie bust starring Aaron Taylor-Johnson and Russell Crowe—is coming soon to digital streaming. Kraven the Hunter ...

"Kraven the Hunter" partial poster featuring Aaron Taylor-Johnson. Kraven the Hunter—the Marvel box office bust starring Aaron Taylor-Johnson and Russell Crowe—debuts on digital streaming this ...